CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...
   GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and...
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation...
Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE)...
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors...
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation...
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation...
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation...